Identification and validation of a novel five-gene signature in high-risk MYCN-not-amplified neuroblastoma
Discover Oncology · 18.09.2024 · 15 (1)
DOI: 10.1007/s12672-024-01318-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Discover Oncology, online erschienen am 18.09.2024. Verfasst von Jin-Xia Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Unit, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200062, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Sailing Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
OBJECTIVE: High-risk neuroblastoma patients often have poor outcomes despite multi-treatment options. The risk stratification of high-risk MYCN-not-amplified (HR-MYCN-NA) patients remains difficult. This study aims to identify a gene set signature that can help further stratify HR-MYCN-NA patients for a potential personalized therapeutic strategy. METHODS: Three microarrays and one single-cell RNA sequence dataset were acquired and analyzed. Firstly, the prognostic-related genes (PRGs) in HR-MYCN-NA tumor cells were identified using TARGET-NB and GSE137804 datasets. Then, the prognostic model was established by LASSO-Cox regression, and verified in external cohort (GSE49710, GSE45547). Moreover, a time-dependent receiver operating characteristic curve (ROC) and area under the ROC (AUC) was used to assess survival prediction. A nomogram was established to predict the 1-, 3- and 5-year overall survival (OS) of HR-MYCN-NA patients. RESULTS: In the training set, a five-PRGs signature, which include GAL, GFRA3, MARCKS, PSMD13, and ZNHIT3 genes, was identified and successfully stratified HR-MYCN-NA patients into ultra-high risk (UHR) and high-risk (HR) subtypes (HR = 4.29, P < 0.001). ROC curve analysis confirmed its predictive power (AUC = 0.74-0.82), suggesting a good predictive efficacy. Consistently, high-risk scores also predicted worse OS (HR = 2, P = 0.033) in the external validation dataset (AUC = 0.67-0.71). Moreover, the overall C-index of the nomogram was 0.75 (P < 0.001), which indicated good agreement between the observed and predicted survival rates. Further integrating the five PRGs signature with clinical factors, these 5 gene signature (HR = 4.45, P < 0.001) and tumor grade (HR = 4.15, P = 0.02) were found to be independent prognostic factors for HR-MYCN-NA patients. CONCLUSION: The novel five PRGs signature could well predict the survival of HR-MYCN-NA patients, which may provide constructive information for these subsets.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Research Unit, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200062, China.
- Institute of Pediatric Infection, Immunity, and Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200062, China.
- Department of Hematology and Cancer, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200062, China. shaojb@shchildren.com.cn.
- Clinical Research Unit, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200062, China. zoulin74@126.com.
- Institute of Pediatric Infection, Immunity, and Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200062, China. zoulin74@126.com.
Förderung
- Shanghai Sailing Program
- National Natural Science Foundation of China
Zitieren
APA
Wang, J. X., Zhang, H. Y., Yan, Z. J., Cao, Z. Y., Shao, J. B., & Zou, L. (2024). Identification and validation of a novel five-gene signature in high-risk MYCN-not-amplified neuroblastoma. Discover Oncology, 15(1). https://doi.org/10.1007/s12672-024-01318-0
Vancouver
Wang JX, Zhang HY, Yan ZJ, Cao ZY, Shao JB, Zou L. Identification and validation of a novel five-gene signature in high-risk MYCN-not-amplified neuroblastoma. Discover Oncology. 2024;15(1). doi:10.1007/s12672-024-01318-0
BibTeX
@article{Wang2024,
author = {Wang, Jin-Xia and Zhang, Hong-Yang and Yan, Zi-Jun and Cao, Zi-Yang and Shao, Jing-Bo and Zou, Lin},
title = {Identification and validation of a novel five-gene signature in high-risk MYCN-not-amplified neuroblastoma},
journal = {Discover Oncology},
year = {2024},
volume = {15},
number = {1},
doi = {10.1007/s12672-024-01318-0}
}
EUVIMED